Zhejiang Jinbikang Pharmaceutical Technology Co., Ltd

To compare the differences in absorption extent and absorption rate of milnacipran hydrochloride tablets (specification: 25 mg) provided by Zhejiang Jinbikang Pharmaceutical Technology Co., Ltd. and milnacipran hydrochloride tablets (trade name: Toledomin®; specification: 25 mg) certified by Asahi Kasei Pharma Co., Ltd. in healthy Chinese population under postprandial administration conditions.

To compare the differences in the extent and rate of absorption of milnacipran hydrochloride tablets (25 mg) provided by Zhejiang Jinbikang Pharmaceutical Technology Co., Ltd. and milnacipran hydrochloride tablets (trade name: Toledomin®; 25 mg) licensed by Asahi Kasei Pharma Co., Ltd. in healthy Chinese subjects under fasting conditions.

The main purpose of the study is to evaluate the pharmacokinetic parameters of the test preparation probucol tablets (specification: 0.25 g) and the reference preparation probucol tablets (Lorelco®, specification: 250 mg, produced by Otsuka Pharmaceutical Co., Ltd.) in healthy participants after a single oral administration in the fed state, and to evaluate the bioequivalence of the two oral preparations in the fed state. Secondary study objective: To evaluate the safety of the test formulation, probucol tablets (strength: 0.25 g) and the reference formulation, probucol tablets (Lorelco®, strength: 250 mg) in healthy participants.